P-1418. Risk for Early and Late Readmission for Serious Injection-Related Infections: the CHOICE+ Cohort

Abstract Background People who inject drugs hospitalized with severe injection-related infections (SIRI) face barriers to antibiotic treatment completion and remain at risk for new infections due to ongoing injection drug use. We explored risk factors for SIRI readmission and whether readmissions were caused by the index SIRI or a new SIRI. Methods CHOICE+ is a retrospective cohort study of adults hospitalized with SIRI due to injection opioid use at 4 hospital systems between 1/1/2018 and 3/31/2022. Data were collected by abstraction of the medical record. Primary outcomes were readmission for SIRI within 1 year and time to readmission. Categorical variables were analyzed by chi-square, Fischer exact test, and multivariate logistic regression. Time to readmission was compared by the Mann-Whitney test. Results Of 1618 patients discharged alive, 439 (27%) had ≥1 readmission for SIRI. Unstable housing, patient-directed discharge, and not finishing planned intravenous antibiotics in the hospital were associated with increased risk for SIRI readmission (Table 2). Risk of SIRI readmission was not associated with addiction or psychiatry consultation, discharge on medication for opioid use disorder (MOUD), or type of MOUD. The cause of readmission in 238 (54%) was the index SIRI and in 201 (46%) was a new SIRI. Median time to readmission was shorter for those readmitted with index SIRI compared to a new SIRI (10 v. 126 days, p < 0.0001, Figure 1) and for those who did not complete treatment for the index SIRI compared to those who completed treatment (7 v. 78 days, p < 0.0001, Figure 2). Conclusion In this large, representative study, readmission for SIRI occurred frequently for both problems related to the index SIRI as well as development of new SIRI. Readmission for index SIRI occurred earlier than for new SIRI, especially for those who did not complete antibiotic treatment. Notably, readmission for SIRI was not associated with inpatient interventions to address addiction during the index hospitalization. Therefore, prioritizing completion of treatment of the index SIRI may be critical for reducing early readmissions. In contrast, prevention of new SIRI, by longitudinally addressing addiction, social determinants of health, and harm reduction, may be necessary to reduce later readmissions. Disclosures Elana S. Rosenthal, MD, Gilead Sciences: Grant/Research Support|Merck: Grant/Research Support

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2025-01-29
DOI
https://doi.org/10.1093/ofid/ofae631.1593
Citations
1
Primary Topic
Botulinum Toxin and Related Neurological Disorders
Type
article
Field-Weighted Citation Impact
1.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-1418. Risk for Early and Late Readmission for Serious Injection-Related Infections: the CHOICE+ Cohort

Sarah Kattakuzhy, Meghan Derenoncourt, Elana Rosenthal, Jillian S. Catalanotti et al.
1 citations
Open Forum Infectious Diseases
Botulinum Toxin and Related Neurological Disorders
1.39
article

P-1418. Risk for Early and Late Readmission for Serious Injection-Related Infections: the CHOICE+ Cohort

Sarah Kattakuzhy, Meghan Derenoncourt, Elana Rosenthal, Jillian S. Catalanotti, Ayako Fujita, Habib Omari, Edward C Traver, Alaina Steck, Joseph Carpenter, Becky Reece, Jasmine Stevens, Irene Kuo, Ishan Kumar Vaish, Sumitha Raman, Hannah E Flores
article en
1 citations

Abstract

Abstract Background People who inject drugs hospitalized with severe injection-related infections (SIRI) face barriers to antibiotic treatment completion and remain at risk for new infections due to ongoing injection drug use. We explored risk factors for SIRI readmission and whether readmissions were caused by the index SIRI or a new SIRI. Methods CHOICE+ is a retrospective cohort study of adults hospitalized with SIRI due to injection opioid use at 4 hospital systems between 1/1/2018 and 3/31/2022. Data were collected by abstraction of the medical record. Primary outcomes were readmission for SIRI within 1 year and time to readmission. Categorical variables were analyzed by chi-square, Fischer exact test, and multivariate logistic regression. Time to readmission was compared by the Mann-Whitney test. Results Of 1618 patients discharged alive, 439 (27%) had ≥1 readmission for SIRI. Unstable housing, patient-directed discharge, and not finishing planned intravenous antibiotics in the hospital were associated with increased risk for SIRI readmission (Table 2). Risk of SIRI readmission was not associated with addiction or psychiatry consultation, discharge on medication for opioid use disorder (MOUD), or type of MOUD. The cause of readmission in 238 (54%) was the index SIRI and in 201 (46%) was a new SIRI. Median time to readmission was shorter for those readmitted with index SIRI compared to a new SIRI (10 v. 126 days, p < 0.0001, Figure 1) and for those who did not complete treatment for the index SIRI compared to those who completed treatment (7 v. 78 days, p < 0.0001, Figure 2). Conclusion In this large, representative study, readmission for SIRI occurred frequently for both problems related to the index SIRI as well as development of new SIRI. Readmission for index SIRI occurred earlier than for new SIRI, especially for those who did not complete antibiotic treatment. Notably, readmission for SIRI was not associated with inpatient interventions to address addiction during the index hospitalization. Therefore, prioritizing completion of treatment of the index SIRI may be critical for reducing early readmissions. In contrast, prevention of new SIRI, by longitudinally addressing addiction, social determinants of health, and harm reduction, may be necessary to reduce later readmissions. Disclosures Elana S. Rosenthal, MD, Gilead Sciences: Grant/Research Support|Merck: Grant/Research Support

Open Forum Infectious DiseasesVol. 12(Supplement_1)
West Virginia University (US), University of Maryland, Baltimore (US), Milken Institute (US), Emory University (US), George Washington University (US), University of Baltimore (US)
Good health and well-being
Openalex Percentile: Top 24%
Botulinum Toxin and Related Neurological Disorders
1.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.